The Milliman Healthcare Inflation Guard ETF (MHIG) aims to counteract the rising expenditures in healthcare, distinct from general economic inflation, by utilizing proprietary actuarial data and sophisticated quantitative modeling. Its analytical foundation relies on Milliman's extensive collection of genuine healthcare claims, encompassing roughly 35 million insured individuals, to project future healthcare inflation through observed trends in medical and pharmacy costs. The fund's investments include a mix of equities and fixed-income securities spanning the entire healthcare supply chain, supplemented by instruments designed to hedge against inflation such as commodities, Treasury Inflation-Protected Securities (TIPS), and U.S. Treasury bonds. A quantitative model typically directs the fund's monthly rebalancing to adapt to changes in U.S. healthcare cost inflation. This strategy dynamically alters its asset allocation, increasing its focus on equities and commodities when inflation is elevated, and shifting towards debt instruments as inflationary pressures subside. The portfolio may also include various derivative instruments like swaps, options, and futures, in addition to exchange-traded funds (ETFs).

Eli Lilly and Company

UnitedHealth Group Incorporated

Thermo Fisher Scientific Inc.

Johnson & Johnson

Abbott Laboratories

Danaher Corporation

AbbVie Inc.

Intuitive Surgical, Inc.

Stryker Corporation

Medtronic plc

Milliman Healthcare Inflation Guard ETF

MHIG Holdings & Sector Breakdown